EW - Edwards Lifesciences Corporation

NYSE - NYSE Delayed Price. Currency in USD
192.15
+3.24 (+1.72%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close188.91
Open188.01
Bid0.00 x 800
Ask0.00 x 900
Day's Range187.56 - 193.04
52 Week Range123.00 - 197.86
Volume859,518
Avg. Volume1,386,341
Market Cap39.922B
Beta (3Y Monthly)0.92
PE Ratio (TTM)56.85
EPS (TTM)3.38
Earnings DateApr 22, 2019 - Apr 26, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est185.19
Trade prices are not sourced from all markets
  • Edwards Lifesciences Presents Positive Partner 3 Trial Data
    Zacks16 hours ago

    Edwards Lifesciences Presents Positive Partner 3 Trial Data

    Edwards Lifesciences (EW) expects SAPIEN 3 to gain FDA approval for the low-risk indication in late-2019.

  • Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
    Zacks18 hours ago

    Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

    Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

  • NASH, Allergies and Beauty Stocks: Invest or Not?
    Zacksyesterday

    NASH, Allergies and Beauty Stocks: Invest or Not?

    There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?

  • 6 Stocks With 'Pricing Power' Poised To Race Ahead of Market
    Investopediayesterday

    6 Stocks With 'Pricing Power' Poised To Race Ahead of Market

    High-margin stocks with 'pricing power' in their markets are well positioned for more gains ahead, according to Goldman Sachs. This group of 50 stocks has posted stunning performance in the past year compared to low-margin stocks, and may outperform in the upcoming period as rising costs continue to pressure U.S. corporations, says Goldman in its latest US Thematic Views report. "Growing margin pressures have driven the outperformance of stocks with high pricing power," the firm says.

  • Medtronic (MDT) Releases Encouraging Evalut TAVR Result
    Zacks2 days ago

    Medtronic (MDT) Releases Encouraging Evalut TAVR Result

    Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.

  • 3 High-Performing Large-Cap Stocks
    GuruFocus.com2 days ago

    3 High-Performing Large-Cap Stocks

    In addition, these stocks received very high ratings from GuruFocus for financial strength as well as profitability and growth. Warning! GuruFocus has detected 5 Warning Sign with EW. Edwards Lifesciences Corp. (EW) has gained 9% over the last week, 8% over the past month, 25% so far this year, 35% over the last 52 weeks and 122% over the past three years through March 18.

  • Edwards Lifesciences (EW) Looks Good: Stock Adds 6.2% in Session
    Zacks3 days ago

    Edwards Lifesciences (EW) Looks Good: Stock Adds 6.2% in Session

    Edwards Lifesciences (EW) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • Company News For Mar 19, 2019
    Zacks3 days ago

    Company News For Mar 19, 2019

    Companies in the news are: OSTK, FIS, WP, EW and DERM

  • Benzinga3 days ago

    The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 18) AstraZeneca plc (NYSE: AZN )(received orphan drug ...

  • Why Edwards Lifesciences, Village Farms International, and Puma Biotechnology Jumped Today
    Motley Fool3 days ago

    Why Edwards Lifesciences, Village Farms International, and Puma Biotechnology Jumped Today

    Earnings momentum and some good business results sent these stocks up.

  • Medical Stock Pops As Its Heart-Valve System Seen 'Usurping' Surgery
    Investor's Business Daily3 days ago

    Medical Stock Pops As Its Heart-Valve System Seen 'Usurping' Surgery

    Edwards stock jumped to a record high Monday after the medtech company's TAVR heart-valve replacement outperformed surgery in a yearlong clinical study. Medtronic and Boston stocks sank.

  • Reuters3 days ago

    US STOCKS-Wall St treads water as Boeing, Facebook weigh; Fed meeting on tap

    The Fed's two-day policy meeting begins on Tuesday, where the central bank is widely expected to keep interest rates steady and reiterate its "patient" approach to monetary policy. Investors will be looking for whether the Fed's dot plot, which shows individual committee members' rate views for the coming three years, aligns with the patient approach.

  • TheStreet.com4 days ago

    Edwards Lifesciences Gains on Positive Heart Trial Results

    gained more than 6% on Monday after the medical research and device company announced positive results related to its recent aortic valve surgical treatment trial. Edwards Lifesciences stock gained $10.91 to $190.66 on the New York Stock Exchange after the company on Saturday said its SAPIEN 3 transcatheter aortic valve proved successful in patient trials vs. more traditional open-heart surgery treatment.

  • CNBC4 days ago

    Stocks making the biggest moves midday: Facebook, Deutsche Bank, Lumber Liquidators & more

    Boeing shares slipped more than 1.5 percent after The Wall Street Journal reported that federal prosecutors and the Department of Transportation are scrutinizing the development of the company's 737 Max jets. An Ethiopian Airlines flight involving the 737 Max 8 crashed on March 10. Facebook FB — Shares of the social media giant fell more than 3 percent after an analyst at Needham downgraded them to hold from buy.

  • Reuters4 days ago

    US STOCKS-Tech boosts Wall Street; Boeing keeps Dow in check

    The S&P 500 and Nasdaq on Monday extended last week's gains, lifted by technology and financial stocks, as investors waited for the Federal Reserve's policy meeting later this week for further clues on the pace of interest rate hikes. At the central bank's two-day policy meeting which starts on Tuesday, the Fed is widely expected to stick to its pledge of a "patient" approach to monetary policy.

  • Reuters4 days ago

    US STOCKS-Wall Street lifted by tech stocks; Boeing drags on Dow

    The S&P 500 and Nasdaq extended last week's gains on Monday, lifted by technology and financial stocks, as investors waited for the Federal Reserve's policy meeting later this week for further clues on the pace of interest rate hikes. The Dow was pressured by Boeing Co, which fell 2.7 percent after Ethiopia said an initial analysis of black boxes showed "clear similarities" in the March 10 plane crash with October's accident in Indonesia.

  • Dow Jones Turns Higher Despite Boeing Stock's Renewed Sell-Off
    Investor's Business Daily4 days ago

    Dow Jones Turns Higher Despite Boeing Stock's Renewed Sell-Off

    The Dow Jones industrials reversed from early losses to turn higher despite Boeing's renewed sell-off. Edwards Lifesciences stock jumped 8%.

  • Stocks Edge Higher, Boeing, Facebook Drag; China Stocks Rally
    Investor's Business Daily4 days ago

    Stocks Edge Higher, Boeing, Facebook Drag; China Stocks Rally

    China stocks and Edwards Lifesciences were early leaders Monday, helping stocks gain strength, even as Boeing weighed on the Dow Jones industrials.

  • The Wall Street Journal4 days ago

    Smaller Hospitals Press for Chance to Offer Heart-Valve Procedure

    A battle has broken out among doctors, hospitals and medical-device makers over whether an increasingly popular but risky medical procedure for replacing defective heart valves should be offered more widely. The fight is over which hospitals can get paid by the federal government to perform the procedure, often referred to as TAVR, for transcatheter aortic valve replacement. Currently, bigger hospitals that perform the procedures more frequently are favored under federal reimbursement policies—based on studies linking volume to quality—while smaller hospitals have a tougher time meeting the rules to start or maintain TAVR offerings.

  • Edwards SAPIEN 3 Valve Proves Superior To Surgery In Partner 3 Trial
    PR Newswire5 days ago

    Edwards SAPIEN 3 Valve Proves Superior To Surgery In Partner 3 Trial

    The trial, which compared treatment with the SAPIEN 3 valve to surgery in patients with severe symptomatic aortic stenosis (AS) at low risk of death from surgery, achieved superiority of its primary endpoint at one year. The results of the trial will be presented on Sunday as part of the late-breaking clinical trials at the American College of Cardiology's 68th Annual Scientific Session (ACC.19) in New Orleans, and have been published online in the New England Journal of Medicine.

  • Reuters6 days ago

    Edwards, Medtronic heart valve systems prove worth in low-risk patients -studies

    Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results that had been scheduled to be presented on Sunday. Both companies already have approvals for their TAVR (transcatheter aortic valve replacement) systems for use in patients too frail to endure surgery and those deemed at intermediate risk. An estimated 165,000 low-risk patients suffer from severe aortic stenosis each year in the United States, Western Europe and Japan, a condition that can lead to heart failure in as little as two years, Medtronic said.

  • Edwards Lifesciences Makes Investments in Heart Failure Space
    Zacks10 days ago

    Edwards Lifesciences Makes Investments in Heart Failure Space

    The two transactions align with Edwards Lifesciences' (EW) goal of making the most innovative medical care available to patients of structural heart disease.

  • Markit10 days ago

    See what the IHS Markit Score report has to say about Edwards Lifesciences Corp.

    Edwards Lifesciences Corp NYSE:EWView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for EW with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold EW had net inflows of $3.54 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GuruFocus.com10 days ago

    Edwards Lifesciences Corp (EW) Chairman & CEO Michael A Mussallem Sold $5.5 million of Shares

    Chairman & CEO of Edwards Lifesciences Corp (NYSE:EW) Michael A Mussallem sold 32,800 shares of EW on 03/08/2019 at an average price of $167.89 a share.

  • How Do Analysts See Edwards Lifesciences Corporation (NYSE:EW) Performing Over The Next Year?
    Simply Wall St.10 days ago

    How Do Analysts See Edwards Lifesciences Corporation (NYSE:EW) Performing Over The Next Year?

    Looking at Edwards Lifesciences Corporation's (NYSE:EW) earnings update on 31 December 2018, it seems that analyst forecasts are substantially optimistic, as a 52% rise in profits is expected in theRead More...